Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Therma Bright Welcomes Healthcare and Technology Expert Steve Raysely to its Advisory Board

By: Newsfile

Announces Shares for Debt Settlements

Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the addition of Steve Raysely to its Advisory Board. With deep experience in healthcare and technology sales, marketing and operations, Mr. Raysely brings a wealth of expertise to the Company's growing advisory team.

Steve Raysely is a distinguished senior executive and strategic advisor with over two decades of experience driving growth, innovation, and operational excellence. Known for his ability to scale businesses and build dynamic go-to-market strategies, Mr. Raysely expertise encompasses leadership in medical device sales, AI-driven healthcare solutions, and strategic partnership development.

As a trusted advisor to Therma Bright, Mr. Raysely will provide invaluable strategic counsel on product market positioning, commercial expansion, and the deployment of emerging health technologies. He draws upon a proven track record of identifying high-growth opportunities, optimizing customer experience and delivering sustained revenue growth.

"We are pleased that Steve has agreed to join our Advisory Board," said Rob Fia, CEO of Therma Bright. "His executive advisory approach centers on scaling distribution operations, pioneering sales, and seamlessly integrating advanced technologies to meet evolving market needs. His visionary leadership and outcome-driven approach make him a pivotal asset to Company's pursuit of transforming innovation into wellness."

Mr. Raysely joins Mr. Sommerville and Mr. Raimondo on the Advisory Board; all of whom are leveraging their networks to introduce Therma Bright, the Venowave VW5 and its other innovative diagnostic and medical device technologies to the U.S. healthcare marketplace.

Debt Settlements
The Company also announces that it has negotiated debt settlements with arm's length creditors. Subject to acceptance by the TSX Venture Exchange, the Company proposes to settle aggregate debt of $168,300 in consideration for which it will issue an aggregate of 3,366,000 common shares at a deemed price of $0.05 per share.

Therma Bright also announces that further to its press release of January 3, 2025, it has now issued an aggregate of 2,825,000 common shares at a deemed price of $0.04 per share to settle aggregate debt of $113,000. All shares issued in relation to this debt settlement are subject to a hold period expiring May 4, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange.

About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.

Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

Follow us on X

FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events and related information such as future sales of Venowave as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239529

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.